Mtambo TR et al., 2024: In silico docking and CYP3A4 screening study predicting that hydrochlorothiazide, a common antihypertensive, inhibits CYP3A4 strongly enough to slow ivermectin clearance. It matters because the people most likely to self-medicate are often on such drugs.
Additionally, a strong inhibition of CYP3A4 by hydrochlorothiazide was observed, suggesting that hydrochlorothiazide's regulatory effects could significantly impede CYP3A4 activity, potentially leading to a reduced metabolism and clearance of ivermectin in the body.
Mtambo TR et al., 2024: In silico docking and CYP3A4 screening study predicting that hydrochlorothiazide, a common antihypertensive, inhibits CYP3A4 strongly enough to slow ivermectin clearance. It matters because the people most likely to self-medicate are often on such drugs. C6 CYP3A4 interaction (in silico). Study type: in silico molecular dynamics plus high-throughput CYP3A4 screening; no human subjects; South Africa (University of Zululand). Dose: not applicable. Comparator: ivermectin alone. Declared conflicts: 'The authors declare no conflicts of interest.' Same caveat as the PBPK row: prediction, not measurement.
